Dicot AB
Dicot Pharma AB engages in the development of pharmaceutical products in Sweden. It develops LIB-01 for the treatment of erectile dysfunction and premature ejaculation. The company was formerly known as Dicot AB (publ) and changed its name to Dicot Pharma AB in May 2024. Dicot Pharma AB was incorporated in 2015 and is based in Uppsala, Sweden.
Market Cap & Net Worth: Dicot AB (DICOT)
Dicot AB (ST:DICOT) has a market capitalization of $64.30 Million (Skr721.35 Million) as of March 18, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #20734 globally and #223 in its home market, demonstrating a 20.88% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Dicot AB's stock price Skr0.36 by its total outstanding shares 2009342502 (2.01 Billion).
Dicot AB Market Cap History: 2025 to 2026
Dicot AB's market capitalization history from 2025 to 2026. Data shows growth from $54.99 Million to $64.30 Million (0.00% CAGR).
Dicot AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Dicot AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of DICOT by Market Capitalization
Companies near Dicot AB in the global market cap rankings as of March 18, 2026.
Key companies related to Dicot AB by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Dicot AB Historical Marketcap From 2025 to 2026
Between 2025 and today, Dicot AB's market cap moved from $54.99 Million to $ 64.30 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr64.30 Million | +16.94% |
| 2025 | Skr54.99 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Dicot AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $64.30 Million USD |
| MoneyControl | $64.30 Million USD |
| MarketWatch | $64.30 Million USD |
| marketcap.company | $64.30 Million USD |
| Reuters | $64.30 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.